Corium Reports Second Quarter Fiscal 2017 Financial Results and Recent Corporate Highlights

MENLO PARK, Calif., May 11, 2017 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second fiscal quarter and the six months ended March 31, 2017, and reported on recent corporate developments.  Corium’s fiscal year ends on September 30.

Recent Corporate Developments

  • Pilot bioequivalence study for Corplex™ Donepezil complete; positive preliminary results reported Corium has completed a three-way crossover pilot bioequivalence study for Corplex Donepezil, a once-weekly transdermal therapeutic for Alzheimer’s disease, comparing steady-state plasma concentrations achieved with the transdermal systems with those of daily oral Aricept® (donepezil hydrochloride) after five weeks of treatment.  The combined preliminary results demonstrated that the Corplex Donepezil product candidate meets the primary statistical criteria for bioequivalence to oral Aricept, and provided clear guidance on the parameters for the company’s upcoming pivotal study.  Corplex Donepezil was well tolerated with favorable adhesion, skin safety and gastrointestinal side effect profiles.  
  • Preparation for pivotal Corplex Donepezil study underway The company expects to initiate the pivotal bioequivalence study this fall, with preliminary topline results expected in February 2018.  Corium is targeting submission of a Section 505(b)(2) New Drug Application (NDA) in the second half of 2018. 
  • New five-year Procter & Gamble agreement Corium and P&G entered into a new commercial supply agreement that, among other things, extends the term of the supply relationship to March 31, 2022.  Corium is the sole supplier to P&G of oral care products incorporating Corium’s proprietary Corplex technology, sold under the brand name Crest® Whitestrips. 
  • Mayne Pharma partnership expanded In March, Mayne Pharma acquired from Par Pharmaceutical the rights to market the fentanyl transdermal delivery system (TDS) manufactured by Corium.  Mayne’s acquisition of this product strengthens the alliance between Corium and Mayne, which encompasses other products developed and manufactured by Corium, including the commercial Clonidine TDS and a development-stage motion sickness patch.
  • Partner Agile Therapeutics to resubmit NDA for Twirla® once-weekly contraceptive Based on recent feedback from the FDA, Agile confirmed that it plans to resubmit the NDA for Twirla by the end of June 2017.  Corium has completed the registration batch, and has provided Agile with all of the Chemistry, Manufacturing and Controls information required for Agile’s resubmission.  Corium is the exclusive manufacturer and supplier of Twirla.

“The second quarter was an especially productive one for Corium, culminating in the recent clinical success of our proprietary Corplex Donepezil product candidate,” said Peter D. Staple, President and Chief Executive Officer of Corium.  “With that data now in hand, we have increased confidence in our ability to bring this important new therapeutic option to Alzheimer’s patients and their caregivers.  In addition, we have strengthened a core component of our partner-focused development and manufacturing business by renewing our strategic oral care relationship with Procter & Gamble for a five-year term, and we also expanded the breadth of our partnership with Mayne Pharma to include additional generic transdermal products.”

Financial Results for the Quarter and Six Months Ended March 31, 2017

Corium reported total revenues in the second quarter of fiscal 2017 of $7.3 million, compared with $7.0 million in the second quarter of fiscal 2016, and for the six-month period ended March 31, 2017 reported total revenues of $14.3 million compared with $14.5 million in the same period of fiscal 2016.  Contract research and development revenues increased for both the second quarter and the six-month period ended March 31, 2017 compared to the same periods in fiscal 2016, primarily as the result of increased activities supporting Agile’s NDA for Twirla.  Product revenues decreased for both the second quarter and the six-month period ended March 31, 2017 compared to same periods in fiscal 2016, primarily as a result of a reduction in demand for both Fentanyl TDS and Clonidine TDS, which were partially offset by an increase in revenues from Crest Whitestrips. 
Total research and development (R&D) expenses in the second quarter of fiscal 2017 were $10.3 million compared with $8.4 million in the second quarter of fiscal 2016, and for the six-month period ended March 31, 2017 total R&D expenses were $18.4 million compared with $15.9 million in the same period of fiscal 2016.  The increase in R&D expenses was driven by Corium’s investment in its proprietary product programs, primarily the advancement of Corplex Donepezil into a pilot bioequivalence study beginning in late fiscal 2016.  This increase in proprietary R&D spending was partially offset by a lower level of resources required for contract research and development programs.

General and administrative (G&A) expenses in the second quarter of fiscal 2017 were $3.0 million compared with the same amount for the second quarter of fiscal 2016, and for the six-month period ended March 31, 2017, total G&A expenses were $6.0 million compared with the same amount for the same period of fiscal 2016.  

Corium reported a net loss for the second quarter of fiscal 2017 of $11.0 million, or $0.42 per share, compared with a net loss of $10.5 million, or $0.47 per share, in the second quarter of fiscal 2016.  For the six-month period ended March 31, 2017, Corium reported a net loss of $21.5 million, or $0.88 per share, compared with a net loss of $19.9 million, or $0.89 per share, in the same period of fiscal 2016.  As of March 31, 2017, there were 29,232,292 shares of Corium common stock outstanding, reflecting the issuance of 6,666,667 shares in connection with a public offering completed in February 2017. 

Cash and cash equivalents as of March 31, 2017 were $40.6 million.

Conference Call and Webcast Details

Corium will host a conference call today at 8:30 a.m. ET (5:30 a.m. PT) to discuss the financial results for the second fiscal quarter ended March 31, 2017 and the preliminary results of the Corplex Donepezil pilot bioequivalence study.  Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international).  The conference ID# is 20268962.  The conference call will also be available via a live audio webcast which may be accessed here or by visiting the Investors section of Corium’s website at where an accompanying slide presentation will be available.  The webcast will be archived on the Corium website for two weeks following the presentation.

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company’s broad experience with advanced transdermal and transmucosal delivery systems.  Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer’s disease.  Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble.  The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins.  The company’s late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners.  For further information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, financial and operating performance, operating costs and expenses, product pipeline, clinical trial and regulatory timing and plans and associated resource requirements, regulatory pathways for our development programs, the achievement of clinical and commercial milestones, and the advancement of our technologies as well as our proprietary, co-developed and partnered products and product candidates.  Forward-looking statements are based on management’s current expectations and projections and are subject to risks and uncertainties, which may cause Corium’s actual results to differ materially from the statements contained herein.  Further information on potential risk factors that could affect Corium’s business and its results are detailed in Corium’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, filed with the Securities and Exchange Commission (SEC) on February 14, 2017, and other reports as filed from time to time with the SEC.  Undue reliance should not be placed on forward-looking statements, especially guidance on future financial or operating performance, which speaks only as of the date they are made.  Corium undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Corplex™ and MicroCor® are trademarks of Corium International Inc.
Twirla® is a registered trademark of Agile Therapeutics, Inc.
Aricept® is a registered trademark of Eisai R&D Management Co, Ltd.
Crest® Whitestrips is a registered trademark of The Procter & Gamble Company.

(In thousands, except share and per share data)
    Three Months Ended
March 31,
  Six Months Ended March
    2017     2016     2017     2016    
Product revenues   $  4,657     $  5,694     $  10,395     $  11,666    
Contract research and development revenues      2,421        975        3,384        2,245    
Other revenues      267        293        534        588    
Total revenues      7,345        6,962        14,313        14,499    
Costs and operating expenses:                          
Cost of product revenues      2,876        4,000        6,957        8,298    
Cost of contract research and development revenues      2,794        2,803        4,914        5,859    
Research and development expenses      7,530        5,593        13,528        10,050    
General and administrative expenses      2,999        2,973        6,004        5,990    
Amortization of intangible assets      178        162        355        321    
Loss on disposal of equipment      —        2        —        2    
Total costs and operating expenses      16,377        15,533        31,758        30,520    
Loss from operations      (9,032 )      (8,571 )      (17,445 )      (16,021 )  
Interest income      44        58        72        88    
Interest expense      (2,049 )      (1,971 )      (4,091 )      (3,948 )  
Loss before income taxes      (11,037 )      (10,484 )      (21,464 )      (19,881 )  
Income tax expense      —        —        2        3    
Net loss and comprehensive loss   $  (11,037 )   $  (10,484 )   $  (21,466 )   $  (19,884 )  
Net loss per share attributable to common stockholders, basic and diluted   $  (0.42 )   $  (0.47 )   $  (0.88 )   $  (0.89 )  
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted      26,487,493        22,255,365        24,448,166        22,221,666    

(In thousands)
    As of
March 31,
   As of
September 30,
    2017     2016    
Current assets:              
Cash and cash equivalents   $  40,574     $  39,833    
Accounts receivable      3,440        4,336    
Unbilled accounts receivable      183        346    
Inventories      2,668        2,424    
Prepaid expenses and other current assets      797        1,341    
Total current assets      47,662        48,280    
Restricted cash      666        666    
Property and equipment, net      11,966        11,147    
Intangible assets, net      7,221        7,057    
TOTAL ASSETS   $  67,515     $  67,150    
Current liabilities:              
Accounts payable   $  3,674     $  2,737    
Accrued expenses and other current liabilities      4,365        4,271    
Long-term debt, current portion      62        77    
Capital lease obligations, current portion      —        72    
Recall liability, current portion      330        460    
Deferred contract revenues, current portion      241        355    
Total current liabilities      8,672        7,972    
Long-term debt, net of current portion      51,485        50,966    
Recall liability, net of current portion      1,717        1,859    
Deferred contract revenues, net of current portion      3,500        3,500    
Total liabilities      65,374        64,297    
Commitments and contingencies              
Stockholders’ equity:              
Common stock      29        22    
Additional paid-in capital      191,066        170,319    
Accumulated deficit      (188,954 )      (167,488 )  
Total stockholders’ equity      2,141        2,853    

Source: Corium


CONTACT: Investor and Media Contact:
SMP Communications
Susan M. Pietropaolo
(201) 923-2049